Trial reportBMJ open respiratory research2019
Long-term effect of azithromycin in bronchiolitis obliterans syndrome.
Trial report in BMJ open respiratory research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Effect of azithromycin on bronchiolitis obliterans syndrome in posttransplant recipients: A systematic review and meta-analysis.Medicine · 2022Pooled it
- Longitudinal lung function trajectories in response to azithromycin therapy for chronic lung disease in children with HIV infection: a secondary analysis of the BREATHE trial.BMC pulmonary medicine · 2024Trial
- Long-Term Macrolides in Chronic Respiratory Diseases: Dusk or a New Dawn? A Narrative Review.Antibiotics (Basel, Switzerland) · 2025Review
- Prophylactic azithromycin for chronic lung allograft dysfunction following lung transplantation: a systematic review and meta-analysis.Journal of thoracic disease · 2025Article
- Postinfectious Bronchiolitis Obliterans in Children.Canadian respiratory journal · 2025Review
- Time to Rethink Bronchiolitis Obliterans Syndrome Following Lung or Hematopoietic Cell Transplantation in Pediatric Patients.Cancers · 2024Review
- Azithromycin Exposure in a 10-Day Window of Myocardial Infarction and Short- and Long-Term Outcomes.JACC. Advances · 2024Article
- Ambient Air Pollution Exposure and Outcomes in Patients Receiving Lung Transplant.JAMA network open · 2024Article
- Decreased Lymphocytic Bronchitis Severity in the Era of Azithromycin Prophylaxis.Transplantation direct · 2023Article
- Bronchiolitis obliterans associated with toxic epidermal necrolysis induced by infection: A case report and literature review.Frontiers in pediatrics · 2023Article
- Effect of Administration of Azithromycin and/or Probiotic Bacteria on Bones of Estrogen-Deficient Rats.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Long-term, low-dose macrolide antibiotic treatment in pediatric chronic airway diseases.Pediatric research · 2022Review
- Systems Biology and Bile Acid Signalling in Microbiome-Host Interactions in the Cystic Fibrosis Lung.Antibiotics (Basel, Switzerland) · 2021Review
- Article
- An update on current treatment strategies for managing bronchiolitis obliterans syndrome after lung transplantation.Expert review of respiratory medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Introduction: Azithromycin stabilises and improves lung function forced expiratory volume in one second (FEV Methods: Eligible patients recruited for the initial randomised placebo-controlled trial received open-label azithromycin after 3 months and were followed up until 6 years after inclusion (n=45) to assess FEV Results: FEV Discussion: Long-term treatment with azithromycin slows down the progression of BOS, although the effect of TLI may affect the observed attenuation of FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.